TargetBeta
IL5
interleukin 5 · also IL-5, EDF, TRF · Interleukins
2 programs in company-led studies act on IL5, from 2 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| depemokimabrule | GlaxoSmithKline | phase 4 | 189 running | – | ChEMBL |
| SHR-1703 | Jiangsu HengRui Medicine | phase 3 | 73 running | – | the company's pipeline |
Conditions their studies are in
- Asthma, 2 programs
- Churg-Strauss Syndrome, 2 programs
- Hypereosinophilic Syndrome, 1 program
- Nasal Polyps, 1 program
- Pulmonary Disease, Chronic Obstructive, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 1, 2027depemokimab · GlaxoSmithKline · phase 4 · NCT07671001
- Apr 2027SHR-1703 · Jiangsu HengRui Medicine · phase 3 · NCT07701239
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.